|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Garvie, CW, Wu, X, Papanastasiou, M, Lee, S, Fuller, J, Schnitzler, GR, Horner, SW, Baker, A, Zhang, T, Mullahoo, JP, Westlake, L, Hoyt, SH, Toetzl, M, Ranaghan, MJ, de Waal, L, McGaunn, J, Kaplan, B, Piccioni, F, Yang, X, Lange, M, Tersteegen, A, Raymond, D, Lewis, TA, Carr, SA, Cherniack, AD, Lemke, CT, Meyerson, M, Greulich, H|
|Date Published||2021 07 16|
|Keywords||Adenosine Monophosphate, Calorimetry, Differential Scanning, Catalytic Domain, Cell Survival, Cryoelectron Microscopy, Cyclic Nucleotide Phosphodiesterases, Type 3, Endoribonucleases, HEK293 Cells, HeLa Cells, Humans, Intracellular Signaling Peptides and Proteins, Kinetics, Mass Spectrometry, Multienzyme Complexes, Mutation, Protein Binding, Protein Conformation, alpha-Helical, Protein Multimerization, Pyridazines, Recombinant Proteins, Tetrahydroisoquinolines|
DNMDP and related compounds, or velcrins, induce complex formation between the phosphodiesterase PDE3A and the SLFN12 protein, leading to a cytotoxic response in cancer cells that express elevated levels of both proteins. The mechanisms by which velcrins induce complex formation, and how the PDE3A-SLFN12 complex causes cancer cell death, are not fully understood. Here, we show that PDE3A and SLFN12 form a heterotetramer stabilized by binding of DNMDP. Interactions between the C-terminal alpha helix of SLFN12 and residues near the active site of PDE3A are required for complex formation, and are further stabilized by interactions between SLFN12 and DNMDP. Moreover, we demonstrate that SLFN12 is an RNase, that PDE3A binding increases SLFN12 RNase activity, and that SLFN12 RNase activity is required for DNMDP response. This new mechanistic understanding will facilitate development of velcrin compounds into new cancer therapies.
|Alternate Journal||Nat Commun|
|PubMed Central ID||PMC8285493|